186 related articles for article (PubMed ID: 11378548)
1. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD.
Rueda A; Sevilla I; Gumà J; Ribelles N; Miramón J; De Las Nieves MA; Márquez A; Alba E
Leuk Lymphoma; 2001 Apr; 41(3-4):353-8. PubMed ID: 11378548
[TBL] [Abstract][Full Text] [Related]
2. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
[TBL] [Abstract][Full Text] [Related]
3. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease.
Gustavsson A
Acta Oncol; 1997; 36(5):483-8. PubMed ID: 9292744
[TBL] [Abstract][Full Text] [Related]
4. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
[TBL] [Abstract][Full Text] [Related]
6. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
9. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
10. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study.
Rueda Domínguez A; Márquez A; Gumá J; Llanos M; Herrero J; de Las Nieves MA; Miramón J; Alba E
Ann Oncol; 2004 Dec; 15(12):1798-804. PubMed ID: 15550585
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).
Levine AM; Li P; Cheung T; Tulpule A; Von Roenn J; Nathwani BN; Ratner L
J Acquir Immune Defic Syndr; 2000 Aug; 24(5):444-50. PubMed ID: 11035615
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.
Dunlop DJ; Eatock MM; Paul J; Anderson S; Reed NS; Soukop M; Lucie N; Fitzsimmons EJ; Tansey P; Steward WP
Clin Oncol (R Coll Radiol); 1998; 10(2):107-14. PubMed ID: 9610900
[TBL] [Abstract][Full Text] [Related]
14. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
15. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.
Nangalia J; Smith H; Wimperis JZ
Leuk Lymphoma; 2008 Aug; 49(8):1530-6. PubMed ID: 18766966
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
Wedgwood A; Younes A
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S63-6. PubMed ID: 18284718
[TBL] [Abstract][Full Text] [Related]
17. Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy.
Cantin G; L'Espérance B; Yelle L; Desjardins L; Couture F; Bergeron M; Lacroix L; Dufresne J; Bélanger D; Ouellet PA; Hewitt LA; Pirc L; Gyger M
Cancer Chemother Pharmacol; 1999; 43(6):503-6. PubMed ID: 10321511
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor.
Gastaldi R; Martino P; Gentile G; Picardi V; De Propris MS; Pirillo MF; De Vellis A; Mandelli F
Ann Oncol; 2002 Jul; 13(7):1158-60. PubMed ID: 12176798
[No Abstract] [Full Text] [Related]
19. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
20. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]